Current and innovative approaches in the treatment of non-muscle invasive bladder cancer: the role of transurethral resection of bladder tumor and organoids.
| Title: | Current and innovative approaches in the treatment of non-muscle invasive bladder cancer: the role of transurethral resection of bladder tumor and organoids. |
|---|---|
| Authors: | Taskovska M; Department of Urology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Department of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Kreft ME; Institute for Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Smrkolj T; Department of Urology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Department of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. |
| Source: | Radiology and oncology [Radiol Oncol] 2020 May 02; Vol. 54 (2), pp. 135-143. Date of Electronic Publication: 2020 May 02. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Sciendo Country of Publication: Poland NLM ID: 9317213 Publication Model: Electronic Cited Medium: Internet ISSN: 1581-3207 (Electronic) Linking ISSN: 13182099 NLM ISO Abbreviation: Radiol Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: [Warsaw, Poland] : Sciendo; Original Publication: Ljubljana : Slovenian Medical Society, Section of Radiology [and] Croatian Medical Association, Croatian Society of Radiology, [1992- |
| MeSH Terms: | Organoids*/cytology ; Organoids*/growth & development ; Organoids*/pathology; Antineoplastic Agents/*administration & dosage ; Electrocoagulation/*methods ; Immunotherapy/*methods ; Urinary Bladder Neoplasms/*therapy; BCG Vaccine/administration & dosage ; Chemotherapy, Adjuvant/methods ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging/classification ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/pathology ; Administration, Intravesical ; Adult Stem Cells ; Artifacts ; Cell Line, Tumor ; Cell Transformation, Neoplastic ; Female ; Humans ; Male ; Neoplasm, Residual ; Pluripotent Stem Cells |
| Abstract: | Background Bladder cancer is the 7th most common cancer in men. About 75% of all bladder cancer are non-muscle invasive (NMIBC). The golden standard for definite diagnosis and first-line treatment of NMIBC is transurethral resection of bladder tumour (TURB). Historically, the monopolar current was used first, today bipolar current is preferred by most urologists. Following TURB, depending on the tumour grade, additional intravesical chemo- or/and immunotherapy is indicated, in order to prevent recurrence and need for surgical resection. Development of new technologies, molecular and cell biology, enabled scientists to develop organoids - systems of human cells that are cultivated in the laboratory and have characteristics of the tissue from which they were harvested. In the field of urologic cancers, the organoids are used mainly for studying the course of different diseases, however, in the field of bladder cancer the data are scarce. Conclusions Different currents - monopolar and bipolar, have different effect on urothelium, that is important for oncological results and pathohistological interpretation. Specimens of bladder cancer can be used for preparation of organoids that are further used for studying carcinogenesis. Bladder organoids are step towards personalised medicine, especially for testing effectiveness of chemo-/immunotherapeutics. |
| References: | Eur Urol. 2009 Aug;56(2):247-56. (PMID: 19409692); Nature. 2009 May 14;459(7244):262-5. (PMID: 19329995); Eur Urol. 2003 Oct;44(4):429-34. (PMID: 14499676); Curr Urol Rep. 2017 May;18(5):34. (PMID: 28283914); Curr Urol Rep. 2016 Mar;17(3):21. (PMID: 26874533); Eur Urol. 2016 Jun;69(6):1046-52. (PMID: 26803476); Infect Immun. 2006 Jan;74(1):750-7. (PMID: 16369034); J Clin Invest. 2010 Jul;120(7):2619-26. (PMID: 20516646); Eur Urol. 2008 Apr;53(4):709-19. (PMID: 18207317); Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4567-4574. (PMID: 30787188); Cell. 2018 Apr 5;173(2):515-528.e17. (PMID: 29625057); Anticancer Res. 2019 Mar;39(3):1105-1118. (PMID: 30842139); Radiol Oncol. 2019 May 8;53(2):131-147. (PMID: 31104002); J Am Coll Surg. 2006 Mar;202(3):520-30. (PMID: 16500257); Eur Urol. 2007 Nov;52(5):1398-406. (PMID: 17485161); Int Urol Nephrol. 2014 Sep;46(9):1699-705. (PMID: 24792236); Stem Cells Transl Med. 2014 May;3(5):610-9. (PMID: 24657961); Nat Rev Urol. 2017 Jul;14(7):401-414. (PMID: 28534535); Eur Urol. 2013 Feb;63(2):234-41. (PMID: 22877502); J Urol. 2002 Nov;168(5):1964-70. (PMID: 12394686); Am J Pathol. 2012 Feb;180(2):599-607. (PMID: 22189618); Virchows Arch. 2015 May;466(5):589-94. (PMID: 25697540); Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. (PMID: 26664503); Nat Rev Urol. 2018 Feb;15(2):92-111. (PMID: 29133939); Transl Androl Urol. 2019 Jul;8(Suppl 3):S300-S302. (PMID: 31392152); Int J Mol Sci. 2014 Apr 25;15(5):7139-57. (PMID: 24776760); J Clin Oncol. 2015 Apr 20;33(12):1348-55. (PMID: 25800753); J Urol. 1976 Aug;116(2):180-3. (PMID: 820877); Cell. 2018 Dec 13;175(7):1972-1988.e16. (PMID: 30550791); Nat Commun. 2019 Sep 27;10(1):4407. (PMID: 31562298); Nature. 2011 Apr 7;472(7341):110-4. (PMID: 21389986); Eur Urol. 2016 Feb;69(2):231-44. (PMID: 26091833) |
| Contributed Indexing: | Keywords: BCG; bladder cancer; mitomycin C; monopolar/bipolar current; organoids; transurethral resection of bladder tumour |
| Substance Nomenclature: | 0 (Antineoplastic Agents); 0 (BCG Vaccine) |
| Entry Date(s): | Date Created: 20200507 Date Completed: 20210712 Latest Revision: 20240729 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7276645 |
| DOI: | 10.2478/raon-2020-0025 |
| PMID: | 32374292 |
| Database: | MEDLINE |
Journal Article; Review